Semaglutide for PCOS Weight Loss UK

Polycystic ovary syndrome (PCOS) affects approximately 1 in 10 women in the UK and is one of the most common endocrine disorders in women of reproductive age. Weight management is disproportionately difficult for women with PCOS, and understanding why is essential context.

How PCOS promotes weight gain:

1. Insulin resistance: 70–80% of women with PCOS have insulin resistance, even at normal weight. High insulin levels promote fat storage, particularly visceral (abdominal) fat, and make fat burning more difficult

2. Androgen excess: Elevated testosterone and other androgens alter fat distribution and may affect metabolism. Women with PCOS tend to accumulate fat around the abdomen rather than hips and thighs

3. Appetite dysregulation: Research shows altered levels of appetite-regulating hormones (ghrelin, cholecystokinin, GLP-1) in women with PCOS, leading to increased hunger and reduced satiety

4. Reduced metabolic rate: Some studies suggest a lower resting metabolic rate in PCOS, meaning fewer calories are burned at rest compared to weight-matched women without PCOS

5. Psychological factors: The distress of PCOS symptoms (acne, hirsutism, irregular periods, infertility) can contribute to emotional eating and reduced motivation for exercise

The clinical significance: - 60–80% of women with PCOS are overweight or obese - Even modest weight loss (5–10%) can significantly improve PCOS symptoms: restored ovulation, improved insulin sensitivity, reduced androgen levels, improved fertility - However, achieving even 5% weight loss is significantly harder with PCOS than without

Current NICE guidance for PCOS weight management (NG217): - Lifestyle modification (diet and exercise) as first-line treatment - No specific weight loss medication recommendation for PCOS in the guidelines - Metformin recommended primarily for metabolic features, not weight loss - This gap in guidance is where GLP-1 agonists are increasingly being used

The evidence base for semaglutide specifically in PCOS is growing, though it remains less extensive than the general obesity literature.

Published studies:

• •STEP trials (general obesity population): Women with PCOS were included in the STEP trial programme. Subgroup analyses showed similar or slightly greater weight loss in women with PCOS compared to those without, which is noteworthy given that PCOS typically makes weight loss harder

• •Dedicated PCOS studies: Several studies have specifically evaluated GLP-1 agonists in women with PCOS:
• • - Semaglutide reduced body weight by 10–15% in PCOS populations over 6–12 months
• • - Significant improvements in insulin resistance (measured by HOMA-IR)
• • - Reductions in testosterone and other androgen levels
• • - Improvements in menstrual regularity and ovulation
• • - Reduced inflammatory markers

• •Liraglutide PCOS data: Earlier studies with liraglutide (a related but less potent GLP-1 agonist) showed meaningful weight loss and metabolic improvement in PCOS. Semaglutide is expected to produce greater effects given its superior efficacy in general obesity

Why GLP-1 agonists are particularly promising for PCOS:

1. Addressing the root cause: Insulin resistance drives much of PCOS pathophysiology. GLP-1 agonists improve insulin sensitivity directly, not just through weight loss

2. Appetite normalisation: GLP-1 agonists may correct the dysregulated appetite hormones seen in PCOS, addressing one of the physiological barriers to weight management

3. Visceral fat reduction: GLP-1 agonists preferentially reduce visceral (abdominal) fat — the type most associated with PCOS metabolic complications

4. Hormonal improvement: Weight loss from GLP-1 agonists has been shown to reduce androgens, improve SHBG (sex hormone binding globulin), and restore menstrual cyclicity

5. Fertility potential: Weight loss and improved insulin sensitivity can restore ovulation. Some PCOS specialists consider GLP-1 agonists as part of pre-conception optimisation (though they must be stopped before pregnancy)

Ongoing research: Several large trials specifically investigating semaglutide and tirzepatide in PCOS populations are underway, with results expected in 2026–2027. These will provide the strongest evidence to date.

Women with PCOS can access semaglutide through several pathways in the UK, though the specific indication matters.

NHS pathways:

1. Through specialist weight management (Tier 3): - PCOS is recognised as a weight-related comorbidity - Women with PCOS and a BMI over 35 (or over 30 with additional comorbidities) are eligible for Wegovy under NICE TA875 - PCOS alone typically meets the comorbidity criterion - Access requires referral through Tier 2 and then Tier 3 weight management services - Waiting times: 6–24 months depending on area

2. Through diabetes services: - Women with PCOS who have developed type 2 diabetes or pre-diabetes can access semaglutide (Ozempic) through their diabetes team - This pathway may be faster than the obesity pathway

3. Through gynaecology/endocrinology: - Some PCOS specialists are prescribing semaglutide or tirzepatide as part of PCOS management - This is somewhat off-label for the PCOS indication itself but within the medication's licence for the weight/diabetes indication - Availability depends on your specialist's approach and local formulary

Private pathways:

1. Private PCOS specialists: - Endocrinologists or gynaecologists with PCOS expertise - Can prescribe semaglutide as part of comprehensive PCOS management - Consultation: £200–£400; medication cost as per standard private pricing

2. Private weight management clinics: - PCOS qualifies as a comorbidity for most private prescribing criteria - Mention your PCOS diagnosis at consultation — it strengthens your case - Online services are typically the most affordable option

3. Online pharmacy services: - Most online GLP-1 prescribing services accept PCOS as a relevant comorbidity - Ensure the service takes a thorough medical history including your PCOS status

Important consideration: When accessing semaglutide for PCOS through any route, ensure your prescriber understands PCOS-specific considerations, particularly regarding fertility (see next section).

Semaglutide and fertility in PCOS is a complex and critically important topic that every prescriber and patient must understand.

The fertility paradox: Semaglutide improves PCOS-related anovulation through weight loss and improved insulin sensitivity. This means women who were previously not ovulating may begin to ovulate again. While this is beneficial if you are trying to conceive (in the future), it creates a risk of unintended pregnancy if you are not using contraception.

Semaglutide and pregnancy — the critical safety information: - Semaglutide is contraindicated in pregnancy (Category X in animal studies showing fetal harm) - You must use reliable contraception while taking semaglutide - Semaglutide should be stopped at least 2 months before planned conception (to allow clearance, given its long half-life of approximately 7 days) - If you become pregnant while taking semaglutide, stop immediately and inform your healthcare team

Contraception while on semaglutide: - GLP-1 agonists slow gastric emptying, which may theoretically reduce absorption of oral contraceptive pills - Consider non-oral contraception: IUD/IUS (coil), contraceptive implant, injection, or barrier methods - If using the combined oral contraceptive pill, be aware of the potential interaction and consider additional precautions - Discuss contraception with your prescriber when starting semaglutide

Pre-conception planning with PCOS: If your goal is to improve fertility through weight loss: 1. Use semaglutide for weight loss and metabolic improvement (6–12 months) 2. Achieve target weight loss (typically 10–15% for meaningful fertility benefit) 3. Stop semaglutide at least 2 months before trying to conceive 4. Transition to lifestyle and dietary management for weight maintenance 5. Begin fertility workup with your gynaecologist 6. Note: Some weight regain after stopping GLP-1 agonists is common

Breastfeeding: - Semaglutide should not be used during breastfeeding - Animal studies show excretion in milk - If you plan to breastfeed, do not restart semaglutide until breastfeeding is complete

The emerging data on "Ozempic babies": Media reports of increased fertility on GLP-1 agonists (so-called "Ozempic babies") largely reflect the expected restoration of ovulation in women with PCOS. This is not a surprise to endocrinologists but highlights the importance of contraception counselling when prescribing GLP-1 agonists to women of reproductive age.

Women with PCOS often take multiple medications. Understanding how semaglutide fits into a comprehensive treatment plan is important.

Semaglutide + Metformin: - This is a very common and generally well-tolerated combination - Metformin addresses insulin resistance through a different mechanism (hepatic glucose output) - The combination may produce greater improvements in insulin sensitivity than either alone - Both can cause GI side effects — titrate both slowly and separately - Many PCOS specialists maintain metformin alongside semaglutide

Semaglutide + Spironolactone: - Spironolactone is commonly used for PCOS-related acne and hirsutism (anti-androgen) - No significant drug interaction with semaglutide - Can be safely combined - Monitor potassium levels as per standard spironolactone monitoring

Semaglutide + Combined Oral Contraceptive (COC): - The COC is commonly prescribed for PCOS to regulate periods, protect the endometrium, and reduce androgens - Potential interaction: semaglutide slows gastric emptying, possibly reducing COC absorption - Practical approach: consider switching to non-oral contraception whilst on semaglutide

Semaglutide + Inositol: - Myo-inositol and D-chiro-inositol are popular supplements for PCOS - Some evidence for improved insulin sensitivity and ovulatory function - No known interaction with semaglutide - Can be safely combined as a supplement

Lifestyle modifications alongside semaglutide: - Reduced appetite from semaglutide is an opportunity to improve diet quality, not just quantity - Prioritise protein intake (1.2–1.6g/kg) to preserve lean mass - Resistance training is particularly important for PCOS (improves insulin sensitivity independently of weight loss) - Regular exercise of any type improves PCOS outcomes - Manage stress — cortisol worsens insulin resistance

Monitoring recommendations for PCOS patients on semaglutide: - HbA1c and fasting glucose every 3 months - Testosterone, SHBG, and DHEAS every 6 months - Lipid profile every 6 months - Liver and kidney function every 6 months - Menstrual cycle tracking (frequency and regularity) - Body composition if possible (weight alone does not capture the metabolic improvements)

*This article is for educational purposes only. PCOS management should involve your GP and/or specialist. Always discuss medication changes with your healthcare team.*